Seminars at Oslo University Hospital

König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, Nygaard GO (2022)
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
JAMA Neurol (in press)
DOI 10.1001/jamaneurol.2021.5109, PubMed 35072702

Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R et al. (2022)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Lancet Haematol (in press)
DOI 10.1016/S2352-3026(21)00381-1, PubMed 35032434

Skotheim RI, Axcrona U, Axcrona K (2022)
Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Eur Urol (in press)
DOI 10.1016/j.eururo.2021.12.031, PubMed 35031159